8-KEarnings & ResultsExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Oct 20, 2005)

Filed October 20, 2005For Securities:PFE

Summary

Pfizer Inc. filed a Form 8-K on October 20, 2005, to report its financial results for the third quarter of 2005. The key information for investors is contained within the press release, which is incorporated as Exhibit 99.1 to this filing. While the 8-K itself does not detail the financial figures, it serves as the official notification of the release of this crucial quarterly performance data. Investors should refer to the press release dated October 20, 2005, for specific details on Pfizer's revenue, earnings, and other key financial metrics for the third quarter of 2005. This filing indicates the public disclosure of the company's operational and financial standing during that period, which is essential for evaluating the company's performance and making informed investment decisions.

Key Highlights

  • 1Pfizer Inc. announced its third quarter 2005 financial results via a press release.
  • 2The press release, dated October 20, 2005, is filed as Exhibit 99.1 to the Form 8-K.
  • 3This 8-K filing serves as official notification of the Q3 2005 financial performance disclosure.
  • 4Investors are directed to the press release for detailed financial information.
  • 5The filing date is October 20, 2005, with the earliest event reported also being October 20, 2005.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and incorporate by reference Pfizer Inc.'s press release detailing its financial results for the third quarter of 2005.

The specific financial results for the third quarter of 2005 are located in the press release dated October 20, 2005, which is filed as Exhibit 99.1 to this Form 8-K. You will need to access that press release for the detailed figures.

No, this Form 8-K filing itself does not provide the specific financial numbers for the third quarter of 2005. It merely states that the results have been released in an accompanying press release (Exhibit 99.1).